Last reviewed · How we verify
Secukinumab 300 mg
Secukinumab 300 mg is a Small molecule drug developed by GWT-TUD GmbH. It is currently FDA-approved. Also known as: COSENTYX ®, AIN457, AIN457 300 mg.
Secukinumab 300 mg is an interleukin 17A inhibitor, classified as an INHIBITOR drug modality, which targets Interleukin-17A. It is used to treat conditions such as moderate to severe plaque-type psoriasis, dermatitis, atopic eczema, and pyoderma gangrenosum, among others.
At a glance
| Generic name | Secukinumab 300 mg |
|---|---|
| Also known as | COSENTYX ®, AIN457, AIN457 300 mg |
| Sponsor | GWT-TUD GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa (PHASE4)
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa (PHASE3)
- Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (PHASE3)
- Secukinumab Open Label Roll-over Extension Protocol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secukinumab 300 mg CI brief — competitive landscape report
- Secukinumab 300 mg updates RSS · CI watch RSS
- GWT-TUD GmbH portfolio CI
Frequently asked questions about Secukinumab 300 mg
What is Secukinumab 300 mg?
Who makes Secukinumab 300 mg?
Is Secukinumab 300 mg also known as anything else?
What development phase is Secukinumab 300 mg in?
Related
- Manufacturer: GWT-TUD GmbH — full pipeline
- Also known as: COSENTYX ®, AIN457, AIN457 300 mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing